These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32471030)

  • 1. Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.
    Castello A; Rossi S; Toschi L; Mansi L; Lopci E
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
    Tiako Meyo M; Jouinot A; Giroux-Leprieur E; Fabre E; Wislez M; Alifano M; Leroy K; Boudou-Rouquette P; Tlemsani C; Khoudour N; Arrondeau J; Thomas-Schoemann A; Blons H; Mansuet-Lupo A; Damotte D; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors.
    Castello A; Carbone FG; Rossi S; Monterisi S; Federico D; Toschi L; Lopci E
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092983
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
    Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
    Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.
    Wu X; Huang Y; Zhao Q; Wang L; Song X; Li Y; Jiang L
    EJNMMI Res; 2020 May; 10(1):51. PubMed ID: 32430866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors.
    Castello A; Rossi S; Toschi L; Lopci E
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33803006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
    Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic activity by
    Kaira K; Higuchi T; Naruse I; Arisaka Y; Tokue A; Altan B; Suda S; Mogi A; Shimizu K; Sunaga N; Hisada T; Kitano S; Obinata H; Yokobori T; Mori K; Nishiyama M; Tsushima Y; Asao T
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):56-66. PubMed ID: 28828507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive significance of soluble programmed death ligand 1 in bronchoalveolar lavage fluid in stage IV non-small cell lung cancer.
    Kim SY; Park D; Sun P; Kim N; Lee D; Kim DK; Lee SI; Lee JE; Chung C; Kang DH
    Transl Lung Cancer Res; 2024 Aug; 13(8):1888-1906. PubMed ID: 39263019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy.
    Krafft U; Olah C; Reis H; Kesch C; Darr C; Grünwald V; Tschirdewahn S; Hadaschik B; Horvath O; Kenessey I; Nyirady P; Varadi M; Modos O; Csizmarik A; Szarvas T
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With
    Jia Y; Li X; Zhao C; Ren S; Su C; Gao G; Li W; Zhou F; Li J; Zhou C
    Front Oncol; 2020; 10():1455. PubMed ID: 32983977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.
    Costantini A; Julie C; Dumenil C; Hélias-Rodzewicz Z; Tisserand J; Dumoulin J; Giraud V; Labrune S; Chinet T; Emile JF; Giroux Leprieur E
    Oncoimmunology; 2018; 7(8):e1452581. PubMed ID: 30221046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Jreige M; Letovanec I; Chaba K; Renaud S; Rusakiewicz S; Cristina V; Peters S; Krueger T; de Leval L; Kandalaft LE; Nicod-Lalonde M; Romero P; Prior JO; Coukos G; Schaefer N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1859-1868. PubMed ID: 31214790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.
    Kashiwada T; Takano R; Ando F; Kuroda S; Miyabe Y; Owada R; Miyanaga A; Asatsuma-Okumura T; Hashiguchi M; Kanazawa Y; Yoshida H; Seike M; Gemma A; Iwai Y
    Front Pharmacol; 2024; 15():1384733. PubMed ID: 38799168
    [No Abstract]   [Full Text] [Related]  

  • 18.
    Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
    Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab.
    Wakita N; Hinata N; Bando Y; Hara T; Terakawa T; Furukawa J; Nakano Y; Fujisawa M
    Anticancer Res; 2023 Feb; 43(2):841-847. PubMed ID: 36697079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC.
    Yi L; Wang X; Fu S; Yan Z; Ma T; Li S; Wei P; Zhang H; Wang J
    Discov Oncol; 2023 Mar; 14(1):35. PubMed ID: 36991160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.